Skip to main content
SpringerLink
Log in

Toxic Neuromuscular Transmission Disorders

  • Chapter
  • First Online:
Myasthenia Gravis and Related Disorders

Part of the book series: Current Clinical Neurology ((CCNEU))

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 249.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Notes

  1. 1.

    While tetanus toxin also binds to the neuromuscular junction, its mechanism of action is distinctly different. This toxin is translocated into the nerve terminal and then moves in a retro-axonal fashion to the synaptic space between the alpha motoneuron and inhibitory neurons. There it inhibits exocytosis resulting in paresis. Because it does not directly involve the motor nerve terminal it will not be discussed further.

REFERENCES

  1. Fambrough DM, Drachman DB, Satymurti S. Neuromuscular function in myasthenia gravis: decreased acetycholine receptors. Science 1973;182:293–295.

    PubMed  CAS  Google Scholar 

  2. Barrons RW. Drug-induced neuromuscular blockade and myasthenia gravis. Pharmacotherapy 1977;17:1220–1232.

    Google Scholar 

  3. Howard JF. Adverse drug effects on neuromuscular transmission. Semin Neurol 1990;10:89–102.

    PubMed  Google Scholar 

  4. Kaeser HE. Drug-induced myasthenic syndromes. Acta Neurologica Scandinavica 1984;70:39–37.

    Google Scholar 

  5. Swift TR. Disorders of neuromuscular transmission other than myasthenia gravis. Muscle & Nerve 1981;4:334–353.

    CAS  Google Scholar 

  6. Argov Z, Mastaglia FL. Disorders of neuromuscular transmission caused by drugs. N Engl J Med 1979;301:409–413.

    PubMed  CAS  Google Scholar 

  7. Pittinger C, Adamson R. Antibiotic blockade of neuromuscular function. Annu Rev Pharmacol 1972;12:109–184.

    Google Scholar 

  8. Singh YN, Marshall IG, Harvey AL. Reversal of antibiotic-induced muscle paralysis by 3, 4- diaminopyridine. J Pharm Pharmacol 1978;30:249.

    PubMed  CAS  Google Scholar 

  9. Caputy AJ, Kim YI, Sanders DB. The neuromuscular blocking effects of therapeutic concentrations of various antibiotics on normal rat skeletal muscle: a quantitative comparison. J Pharmacol Exp Therapeut 1981;217:369–378.

    CAS  Google Scholar 

  10. Snavely SR, Hodges GR. The neurotoxicity of antibacterial agents. [Review] [293 refs]. Ann Intern Med 1984;101:92–104.

    PubMed  CAS  Google Scholar 

  11. Cadisch R, Streit E, Hartmann K. [Exacerbation of pseudoparalytic myasthenia gravis following azithromycin (Zithromax)]. [German]. Schweizerische Medizinische Wochenschrift 1996;Journal Suisse de Medecine. 126:308–310.

    Google Scholar 

  12. Perrot X, Bernard N, Vial C, Antoine JC, Laurent H, Vial T, Confavreux C, Vukusic S. Myasthenia gravis exacerbation or unmasking associated with telithromycin treatment. Neurology 2006;67:2256–2258.

    PubMed  CAS  Google Scholar 

  13. Roquer J, Cano A, Seoane JL, Pou Serradell A. Myasthenia gravis and ciprofloxacin [letter]. Acta Neurologica Scandinavica 1996;94:419–420.

    PubMed  CAS  Google Scholar 

  14. Samuelson RJ, Giesecke AH Jr, Kallus FT, Stanley VF. Lincomycin-curare interaction. Anesth Analg 1975;54:103–105.

    PubMed  CAS  Google Scholar 

  15. Fogdall RP, Miller RD. Prolongation of a pancuronium-induced neuromuscular blockade by clindamycin. Anesthesiology 1974;41:407–408.

    PubMed  CAS  Google Scholar 

  16. McQuillen MP, Engbaek L. Mechanism of colistin-induced neuromuscular depression. Arch Neurol 1975;32:235–238.

    PubMed  CAS  Google Scholar 

  17. Moore B, Safani M, Keesey J. Possible exacerbation of myasthenia gravis by ciprofloxacin [letter]. Lancet 1988;1:882.

    PubMed  CAS  Google Scholar 

  18. Decker DA, Fincham RW. Respiratory arrest in myasthenia gravis with colistimethate therapy. Arch Neurol 1971;25:141–144.

    PubMed  CAS  Google Scholar 

  19. Argov Z, Brenner T, Abramsky O. Ampicillin may aggravate clinical and experimental myasthenia gravis. Arch Neurol 1986;43:255–256.

    PubMed  CAS  Google Scholar 

  20. Howard JF Jr. Adverse drug effects on neuromuscular transmission. [Review] [202 refs]. Semin Neurol 1990;10:89–102.

    PubMed  Google Scholar 

  21. Howard JF, Johnson BR, Quint SR. The effects of beta-adrenergic antagonists on neuromuscular transmission in rat skeletal muscle. Society for Neuroscience abstracts 1987;13:147.

    Google Scholar 

  22. Coppeto JR. Timolol-associated myasthenia gravis. Am J Ophthalmol 1984;98:244–245.

    PubMed  CAS  Google Scholar 

  23. Verkijk, A. Worsening of myasthenia gravis with timolol maleate eyedrops. Ann Neurol 1985;17:211–212.

    PubMed  CAS  Google Scholar 

  24. Bikhazi GB, Leung I, Foldes FF. Interaction of neuromuscular blocking agents with calcium channel blockers. Anesthesiology 1982;57:A268.

    Google Scholar 

  25. Van der Kloot W, Kita H. The effects of verapamil on muscle action potentials in the frog and crayfish and on neuromuscular transmission in the crayfish. Comp Biochem Physiolo 1975;50C:121–125.

    Google Scholar 

  26. Ribera AB, Nastuk WL. The actions of verapamil at the neuromuscular junction. Comp Biochem Physiol C: Comp Pharmacol Toxicol 1989;93C:137–141.

    CAS  Google Scholar 

  27. Adams RJ, Rivner MH, Salazar J, Swift TR. Effects of oral calcium antagonists on neuromuscular transmission. Neurology 1984;34:132–133.

    Google Scholar 

  28. Krendel DA, Hopkins LC. Adverse effect of verapamil in a patient with the Lambert-Eaton syndrome. Muscle & Nerve 1986;9:519–522.

    CAS  Google Scholar 

  29. Kornfeld P, Horowitz SH, Genkins G, Papatestas AE. Myasthenia gravis unmasked by antiarrhythmic agents. Mt Sinai J Med 1976;43:10–14.

    PubMed  CAS  Google Scholar 

  30. Lecky BR, Weir D, Chong E. Exacerbation of myasthenia by propafenone [letter]. J Neurol, Neurosurg Psychiatry 1991;54:377

    CAS  Google Scholar 

  31. Fierro B Castiglione MG, Salemi G, Savettieri G. Myasthenia-like syndrome induced by cardiovascular agents. Report of a case. Ital J Neurol Sci 1987;8:167–169.

    Google Scholar 

  32. Weisman SJ. Masked myasthenia gravis. JAMA 1949;141:917–918.

    CAS  Google Scholar 

  33. Shy ME, Lange DJ, Howard JF, Gold AP, Lovelace RE, Penn AS. Quinidine exacerbating myasthenia gravis: a case report and intracellular recordings. Ann Neurol 1985;18:120.

    Google Scholar 

  34. Stoffer SS, Chandler JH. Quinidine-induced exacerbation of myasthenia gravis in patient with myasthenia gravis. Arch Intern Med 1980;140:283–284.

    PubMed  CAS  Google Scholar 

  35. Miller RD, Way WL, Katzung BG. The neuromuscular effects of quinidine. Proc Soc Exp Biol Med 1968;129:215–218.

    PubMed  CAS  Google Scholar 

  36. Cartwright MS, Jeffery DR, Nuss GR, Donofrio PD. Statin-associated exacerbation of myasthenia gravis. Neurology 2004;63:2188.

    PubMed  Google Scholar 

  37. Engel WK. Reversible ocular myasthenia gravis or mitochondrial myopathy from statins? Lancet 2003;361:85–86.

    PubMed  CAS  Google Scholar 

  38. O'Riordan J, Javed M, Doherty C, Hutchinson M. Worsening of myasthenia gravis on treatment with imipenem/cilastatin [letter]. J Neurol Neurosurg Psychiatry 1994;57:383

    PubMed  Google Scholar 

  39. Parmar B, Francis PJ, Ragge NK. Statins, fibrates, and ocular myasthenia. Lancet 2002;360:717

    PubMed  Google Scholar 

  40. Purvin V, Kawasaki A, Smith KH, Kesler A. Statin-associated myasthenia gravis: report of 4 cases and review of the literature. Medicine (Baltimore) 2006;85:82–85.

    Google Scholar 

  41. Law M, Rudnicka AR. Statin safety: a systematic review. Am J Cardiol 2006;97:S52–S60.

    Google Scholar 

  42. Jacobson TA. Statin safety: lessons from new drug applications for marketed statins. Am J Cardiol 2006;97:S44–S51.

    Google Scholar 

  43. Huynh T, Cordato D, Yang F, Choy T, Johnstone K, Bagnall F, Hitchens N, Dunn R. HMG CoA reductase-inhibitor-related myopathy and the influence of drug interactions. Intern Med J 2002;32:486–490.

    PubMed  CAS  Google Scholar 

  44. Evans M, Rees A. Effects of HMG-CoA reductase inhibitors on skeletal muscle: are all statins the same? Drug Saf 2002;25:649–663.

    PubMed  CAS  Google Scholar 

  45. Youssef S, Stuve O, Patarroyo JC, Ruiz PJ, Radosevich JL, Hur EM, Bravo M, Mitchell DJ, Sobel RA, Steinman L, Zamvil SS. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 2002;420:78–84.

    PubMed  CAS  Google Scholar 

  46. Milani M, Ostlie N, Wang W, Conti-Fine BM. T cells and cytokines in the pathogenesis of acquired myasthenia gravis. Ann NY Acad Sci 2003;998:284–307.

    PubMed  CAS  Google Scholar 

  47. Hargreaves IP, Heales S. Statins and myopathy. Lancet 2002;359:711–712.

    PubMed  Google Scholar 

  48. Wierzbicki AS, Poston R, Ferro A. The lipid and non-lipid effects of statins. Pharmacol Ther 2003;99:95–112.

    PubMed  CAS  Google Scholar 

  49. Krendel DA. Hypermagnesemia and neuromuscular transmission. Semin Neurol 1990;10:42–45.

    PubMed  CAS  Google Scholar 

  50. Castlebaum AR, Donofrio PD, Walker FO, Troost BT. Laxative abuse causing hypermagnesemia quadriparesis and neuromuscular junction defect. Neurology 1989;39:746–747.

    Google Scholar 

  51. Randall RE, Cohen MD, Spray CC, Rossmeise EC. Hypermagnesemia in renal failure. Ann Intern Med 1964;61:73–88.

    PubMed  CAS  Google Scholar 

  52. Collins EN, Russell PW. Fatal magnesium poisoning. Cleve Clin Q 2002;16:162–166.

    Google Scholar 

  53. Mordes JP, Wacker WEC. Excess magnesium. Pharmacol Rev 1978;29:273–300.

    Google Scholar 

  54. Flowers CJ. Magnesium in obstetrics. Am J Obstet Gynecol 1965;91:763–776.

    PubMed  Google Scholar 

  55. Lipsitz PJ. The clinical and biochemical effects of excess magnesium in the newborn. Pediatrics 1971;47:501–509.

    PubMed  CAS  Google Scholar 

  56. Pritchard JA. The use of magnesium sulfate in preeclampsia/eclampsia. J Reprod Med 1979;23:107–114.

    PubMed  CAS  Google Scholar 

  57. Fishman RA. Neurological aspects of magnesium metabolism. Arch Neurol 1965;12:562–596.

    PubMed  CAS  Google Scholar 

  58. Somjen G, Hilmy M, Stephen CR. Failure to anesthetize human subjects by intravenous administration of magnesium sulfate. J Pharmacol Exp Ther 1966;154:652–659.

    PubMed  CAS  Google Scholar 

  59. Hutter OF, Kostial K. Effect of magnesium ions upon the release of acetylcholine. J Physiol 1953;120:53P

    PubMed  CAS  Google Scholar 

  60. Swift TR. Weakness from magnesium containing cathartics. Muscle Nerve 1979;2:295–298.

    PubMed  CAS  Google Scholar 

  61. Del Castillo J, Engback L. The nature of the neuromuscular block produced by magnesium. J Physiol 1954;124:370–384.

    PubMed  CAS  Google Scholar 

  62. De Silva AJC. Magnesium intoxication: an uncommon cause of prolonged curarization. Br J Anaesth 1973;45:1228–1229.

    PubMed  Google Scholar 

  63. Ghoneim MM, Long JP. The interaction between magnesium and other neuromuscular blocking agents. Anesthesiology 1970;32:23–27.

    PubMed  CAS  Google Scholar 

  64. Cohen BA, London RS, Goldstein PJ. Myasthenia gravis and preeclampsia. Obstet Gynecol 1976;48:35S–37S.

    PubMed  CAS  Google Scholar 

  65. George WK, Han CL. Calcium and magnesium administration in myasthenia gravis. Lancet 1962;ii:561.

    Google Scholar 

  66. Gutmann L, Takamori M. Effect of Mg++ on neuromuscular transmission in the Eaton-Lambert syndrome. Neurology 1973;23:977–980.

    PubMed  CAS  Google Scholar 

  67. Strieb EW. Adverse effects of magnesium salt cathartics in a patient with the myasthenic syndrome. Ann Neurol 1973;2:175–176.

    Google Scholar 

  68. Bashuk RG, Krendel DA. Myasthenia gravis presenting as weakness after magnesium administration. Muscle Nerve 1990;13:708–712.

    PubMed  CAS  Google Scholar 

  69. Berciano J, Oterino A, Rebollo M, Pascual J. Myasthenia gravis unmasked by cocaine abuse. N Engl J Med 1991;325:892.

    PubMed  CAS  Google Scholar 

  70. Daras M, Samkoff LM, Koppel BS. Exacerbation of myasthenia gravis associated with cocaine use. Neurology 1996;46:271–272.

    PubMed  CAS  Google Scholar 

  71. Venkatesh S, Rao A, Gupta R. Exacerbation of myasthenia gravis with cocaine use [letter]. Muscle Nerve 1996;19:1364

    PubMed  CAS  Google Scholar 

  72. Krivoshein AV, Hess GP. Mechanism-based approach to the successful prevention of cocaine inhibition of the neuronal (alpha3beta4) nicotinic acetylcholine receptor. Biochemistry 2004;43:481–489.

    PubMed  CAS  Google Scholar 

  73. Balint G, Szobor A, Temesvari P, Zahumenszky Z, Bozsoky S. Myasthenia gravis developed under d-penicillamine treatment. Scan J Rheumatol 1975;12–21.

    Google Scholar 

  74. Bucknall RC, Dixon A, Glick EN, Woodland J, Zutshi DW. Myasthenia gravis associated with penicillamine treatment for rheumatoid arthritis. Br Med J 1975;1:600–602.

    PubMed  CAS  Google Scholar 

  75. Czlonskowska A. Myasthenia syndrome during penicillamine treatment. Br Med J 1975;2:726–727.

    Google Scholar 

  76. Masters CL, Dawkins RL, Zilko PJ, Simpson JA, Leedman RJ Penicillamine-associated myasthenia gravis, antiacetylcholine receptor and antistriational antibodies. Am J Med 1977;63:689–694.

    PubMed  CAS  Google Scholar 

  77. Albers JW, Beals CA, Levine SP. Neuromuscular transmission in rheumatoid arthritis, with and without penicillamine treatment. Neurology 1981;31:1562–1564.

    PubMed  CAS  Google Scholar 

  78. Robberecht W, Bednarik J, Bourgeois P, Van Hees J, Carton H. Myasthenic syndrome caused by direct effect of chloroquine on neuromuscular junction. Arch Neurol 1989;46:464–468.

    PubMed  CAS  Google Scholar 

  79. Perez A, Perella M, Pastor E, Cano M, Escudero J. Myasthenia gravis induced by alpha-interferon therapy. Am J Hematol 1995;49:365–366.

    PubMed  CAS  Google Scholar 

  80. Batocchi AP, Evoli A, Servidei S, Palmisani MT, Apollo F, Tonali P. Myasthenia gravis during interferon alfa therapy. Neurology 1995;45:382–383.

    PubMed  CAS  Google Scholar 

  81. Lensch E, Faust J, Nix WA, Wandel E. Myasthenia gravis after interferon alpha treatment. Muscle Nerve 1996;19:927–928.

    PubMed  CAS  Google Scholar 

  82. Piccolo G, Franciotta D, Versino M, Alfonsi E, Lombardi M, Poma G. Myasthenia gravis in a patient with chronic active hepatitis C during interferon-alpha treatment [letter]. J Neurol, Neurosurg Psychiatry 1996;60:348

    CAS  Google Scholar 

  83. Mase G, Zorzon M, Biasutti E, Vitrani B, Cazzato G, Urban F, Frezza M. Development of myasthenia gravis during interferon-alpha treatment for anti-HCV positive chronic hepatitis [letter]. J Neurol Neurosurg Psychiatry 1996;60:348–349.

    PubMed  CAS  Google Scholar 

  84. Konishi, T. [A case of myasthenia gravis which developed myasthenic crisis after alpha-interferon therapy for chronic hepatitis C]. [Review] [14 refs] [Japanese]. Rinsho Shinkeigaku – Clinical Neurology 1996;36:980–985.

    PubMed  CAS  Google Scholar 

  85. Gu D, Wogensen L, Calcutt N, Zhu S, Merlie JP, Fox HS, Lindstrom JM, Powell HC, Sarvetnick N. Myasthenia gravis-like syndrome induced by expression of interferon in the neuromuscular junction. J Exp Med 1995;18:547–557.

    Google Scholar 

  86. Erbguth F, Claus D, Engelhardt A, Dressler D. Systemic effect of local botulinum toxin injections unmasks subclinical Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry 1993;56:1235–1236.

    PubMed  CAS  Google Scholar 

  87. Borodic G. Myasthenic crisis after botulinum toxin. Lancet 1998;352:1832

    PubMed  CAS  Google Scholar 

  88. Emmerson J. Botulinum toxin for spasmodic torticollis in a patient with myasthenia gravis. Mov Disord 1994;9:367

    PubMed  CAS  Google Scholar 

  89. Tarsy D, Bhattacharyya N, Borodic G. Myasthenia gravis after botulinum toxin A for Meige syndrome. Mov Disord 2000;15:736–738.

    PubMed  CAS  Google Scholar 

  90. Martinez-Matos JA, Gascon J, Calopa M, Montero J. [Myastenia gravis unmasked by botulinum toxin]. Neurologia 2003;18:234–235.

    PubMed  CAS  Google Scholar 

  91. Goncalves MR, Barbosa ER, Zambon AA, Marchiori PE. Treatment of cervical dystonia with botulinum toxin in a patient with myasthenia gravis. Arq Neuropsiquiatr 1999;57:683–685.

    PubMed  CAS  Google Scholar 

  92. Fasano A, Bentivoglio AR, Ialongo T, Soleti F, Evoli A. Treatment with botulinum toxin in a patient with myasthenia gravis and cervical dystonia. Neurology 2005;64:2155–2156.

    PubMed  CAS  Google Scholar 

  93. Cherington M. Clinical spectrum of botulism. Muscle Nerve 1998;21:701–710.

    PubMed  CAS  Google Scholar 

  94. Pickett J, Berg B, Chaplin E, Brunstetter-Shafer, M. Syndrome of botulism in infancy: clinical and electrophysiologic study. N Engl J Med 1976;295:770–792.

    PubMed  CAS  Google Scholar 

  95. MacDonald KL, Rutherford SM, Friedman SM, Dieter JA, Kaye BR, McKinley GF, Tenney JH, Cohen ML. Botulism and botulism-like illness in chronic drug users. Ann Intern Med 1985;102:616–618.

    PubMed  CAS  Google Scholar 

  96. Chia JK, Clark JB, Ryan CA, Pollack M. Botulism in an adult associated with food-borne intestinal infection with Clostridium botulinum. N Engl J Med 1986;315:239–241.

    PubMed  CAS  Google Scholar 

  97. Dowell VR Jr, McCroskey LM, Hatheway CL, Lombard GL, Hughes JM, Merson MH. Coproexamination for botulinal toxin and clostridium botulinum. A new procedure for laboratory diagnosis of botulism. JAMA 1977;238:1829–1832.

    PubMed  Google Scholar 

  98. McCroskey LM, Hatheway CL, Woodruff BA, Greenberg JA, Jurgenson P. Type F botulism due to neurotoxigenic Clostridium baratii from an unknown source in an adult. J Clin Microbiol 1991;29:2618–2620.

    PubMed  CAS  Google Scholar 

  99. Griffin PM, Hatheway CL, Rosenbaum RB, Sokolow R. Endogenous antibody production to botulinum toxin in an adult with intestinal colonization botulism and underlying Crohn's disease. J Infect Dis 1997;175:633–637.

    PubMed  CAS  Google Scholar 

  100. Maretic, Z. Venoms of Theridiidae, genus Latrodectus. B. Epidemiology of envenomation, symptomatology, pathology and treatment. In Arthropod Venoms. Handbuch der experimentellen Pharmakologie. Volume 48 (S. Bettini, ed.) Springer Verlan, Berlin. 1978 pp. 185–207.

    Google Scholar 

  101. Rosenthal L. Alpah-lathrotoxin and related toxins. Pharmacolo Ther 1989;42:115–134.

    CAS  Google Scholar 

  102. Hurlbut WP, Iezzi N, Fesce R, Ceccarelli B. Correlation between quantal secretion and vesicle loss at the frog neuromuscular junction. J Physiol 1990;424:501–526.

    Google Scholar 

  103. Henkel AW, Sankaranarayanan S. Mechanisms of α-latrotoxin action. Cess Tissue Res 1999;296:229–233.

    CAS  Google Scholar 

  104. Ushkaryov YA, Petrenko AG, Geppert M, Sudhof TC. Neurexins: Synaptic cell surface proteins related to the α-lathrotoxin receptor and laminin. Science 1992;257:50–56.

    PubMed  CAS  Google Scholar 

  105. Longenecker HE, Hurlbut WP, Mauro A, Clark AW. Effects of black widow spider venom on the frog neuromuscular junction. Effects on end-plate potential, miniature end-plate potential and nerve terminal spike. Nature 1970;225:701–703.

    PubMed  Google Scholar 

  106. Clark AW, Hurlbut WP, Mauro A. Changes in the fine structure of the neuromuscular junction of the frog caused by black widow spider venom. J Cell Biol 1972;52:1–14.

    PubMed  CAS  Google Scholar 

  107. Clark AW, Mauro A, Longenecker HE, Hurlbut WP. Effects of black widow spider venom on the frog neuromuscular junction. Effects on the fine structure of the frog neuromuscular junction. Nature 1970;225:703–705.

    PubMed  CAS  Google Scholar 

  108. Ceccarelli B, Grohovaz F, Hurlbut WP. Freeze-fracture studies of frog neuromuscular junctions during intense release of neurotransmitter. I. Effects of black widow spider venom and Ca2+-free solutions on the structure of the active zone. J Cell Biol 1979;81:163–177.

    PubMed  CAS  Google Scholar 

  109. Pumplin DW, Reese TS. Action of brown widow spider venom and botulinum toxin on the frog neuromuscular junction examined with the freeze-fracture technique. J Physiol 1977;273:443–457.

    PubMed  CAS  Google Scholar 

  110. Gorio A, Rubin LL, Mauro A. Double mode of action of black widow spider venom on frog neuromuscular junction. J Neurocytol 1978;7:193–202.

    PubMed  CAS  Google Scholar 

  111. Howard BD. Effects and mechanisms of polypeptide neurotoxins that act presynaptically. Ann Rev Pharmacol Toxicol 1980;20:307–336.

    CAS  Google Scholar 

  112. Gilbert WW, Stewart CM. Effective treatment of arachiodism by calcium salts. Am J Med Sci 1935;189:532–536.

    Google Scholar 

  113. Miller TA. Bite of the black widow spider. Am Fam Physician 1992;45:181–187.

    PubMed  CAS  Google Scholar 

  114. D'Amour EF, Becker FE, Van Riper W. The black widow spider. Q Rev Biol 1936;11:123–160.

    Google Scholar 

  115. Temple IU. Acute ascending paralysis, or tick paralysis. Med Sentinel 1912;20:507–514.

    Google Scholar 

  116. Todd JL. Tick bite in British Columbia. CMAJ 1912;2:1118–1119.

    CAS  Google Scholar 

  117. Cleland JB. Injuries and diseases of man in Australia attributable to animals (except insects). Australas Med Gaz 1912;32:295–299.

    Google Scholar 

  118. Gregson, JD. Tick paralysis: an appraisal of natural and experimental data. Monograph Canadian Department of Agriculture 973;9:4–109.

    Google Scholar 

  119. Tick paralysis – Washington, 1995. From the Centers for Disease Control and Prevention. JAMA 1996;275:1470

    Google Scholar 

  120. Gothe R, Kunze K, Hoogstraal H. The mechanisms of pathogenicity in the tick paralyses. J Med Entomol 1979;16:357–369.

    PubMed  CAS  Google Scholar 

  121. Weingart JL. Tick paralysis. Minn Med 1967;50:383–386.

    PubMed  CAS  Google Scholar 

  122. Brown AF, Hamilton DL. Tick bite anaphylaxis in Australia. J Accid Emerg Med 1998;15:111–113.

    PubMed  CAS  Google Scholar 

  123. Felz MW, Smith CD, Swift TR. A six-year-old girl with tick paralysis [see comments]. N Engl J Med 2000;342:90–94.

    PubMed  CAS  Google Scholar 

  124. Cherington M, Synder RD. Tick paralysis. Neurophysiologic studies. N Engl J Med 1968;278:95–97.

    PubMed  CAS  Google Scholar 

  125. Swift TR, Ignacio OJ. Tick paralysis: electrophysiologic studies. Neurology 1975;25:1130–1133.

    PubMed  CAS  Google Scholar 

  126. Grattan-Smith PJ, Morris JG, Johnston HM, Yiannikas C, Malik R, Russell R, Ouvrier RA. Clinical and neurophysiological features of tick paralysis. Brain 1997;120:1975–1987.

    PubMed  Google Scholar 

  127. Donat JR, Donat JF. Tick paralysis with persistent weakness and electromyographic abnormalities. Arch Neurol 1981;38:59–61.

    PubMed  CAS  Google Scholar 

  128. Lagos JC, Thies RE. Tick paralysis without muscle weakness. Arch Neurol 1969;21:471–474.

    PubMed  CAS  Google Scholar 

  129. Rose I. A review of tick paralysis. Can Med Assoc J 1954;70:175–176.

    PubMed  CAS  Google Scholar 

  130. Dworkin MS, Shoemaker PC, Anderson DE. Tick paralysis: 33 human cases in Washington State, 1946–1996. Clin Infect Dis 1999;29:1435–1439.

    PubMed  CAS  Google Scholar 

  131. Jones HR, Jr. Guillain-Barre syndrome in children. Curr Opin Pediatr 1995;7:663–668.

    PubMed  Google Scholar 

  132. Stanbury JB, Huyck JH. Tick paralysis: critical review. Medicine 1945;24:219–242.

    Google Scholar 

  133. Stone BF, Aylward JH. Holocyclotoxin – the paralysing toxin of the austrlian paralsys tick Ixodus holocyclus; chemical and immunological characterization. Toxicon 1992;30:552–553.

    Google Scholar 

  134. Rose I, Gregson JD. Evidence of neuromuscular block in tick paralysis. Nature 1959;178:95–96.

    Google Scholar 

  135. Gothe R, Neitz AWH. Tick paralyses: Pathogensis and etiology. Adv Dis Vector Res 1991;8:177–204.

    Google Scholar 

  136. Stone BF. Tick paralysis, particularly involving Ixodes holocyclus and other Ixodes species. Adv Dis Vector Res 1988;5:61–85.

    Google Scholar 

  137. Esplin DW, Phillip CB, Hughes LE. Impairment of muscle stretch reflexes in tick paralysis. Science 1960;132:958–959.

    PubMed  CAS  Google Scholar 

  138. Cherington M, Snyder RD. Tick paralysis: neurophysiological studies. N Engl J Med 1968;278:95–97.

    PubMed  CAS  Google Scholar 

  139. DeBusk FL, O'Connor S. Tick toxicosis. Pediatrics 1972;50:329–329.

    Google Scholar 

  140. Haller JS, Fabara JA. Tick paralysis. Case report with emphasis on neurological toxicity. Am J Dis Child 1972;124:915–917.

    PubMed  CAS  Google Scholar 

  141. Warnick JE, Albuquerque EX, Diniz CR. Electrophysiological observations on the action of the purified scorpion venom, Tityus-toxin, on nerve and skeletal muscle of the rat. J Pharmacol Exp Ther 1976;198:155–167.

    PubMed  CAS  Google Scholar 

  142. Belghith M, Boussarsar M, Haguiga H, Besbes L, Elatrous S, Touzi N, Boujdaria R, Bchir A, Nouira S, Bouchoucha S, Abroug F. Efficacy of serotherapy in scorpion sting: a matched-pair study. J Toxicol Clin Toxicol 1999;37:51–57.

    PubMed  CAS  Google Scholar 

  143. Sofer S, Shahak E, Gueron M. Scorpion envenomation and antivenom therapy. Pediatrics 1994;124:973–978.

    CAS  Google Scholar 

  144. Campbell CH. The effects of snake venoms and their neurotoxins on the nervous system of man and animals. Contemp Neurol Ser 1975;12:259–293.

    PubMed  CAS  Google Scholar 

  145. Vital Brazil O. Venoms: their inhibitory action on neuromuscular transmission. In: Cheymol, J., Editor, Neuromuscular Blocking and Stimulating Agents, Pergamon Press, New York, 1972 pp. 145–167.

    Google Scholar 

  146. Lee CY. Elapid neurotoxins and their mode of action. Clin Toxicol 1970;3:457–472.

    PubMed  CAS  Google Scholar 

  147. Karlsson E, Arnberg H, Eaker D. Isolation of the principal neurotoxin of tow Naja naja subspecies. Eur J Biochem 1971;21:1–16.

    PubMed  CAS  Google Scholar 

  148. Lee CY, Chang SL, Kau ST, Luh SH. Chromatographic separation of the venon of Bungarus multicinctus and characteristics of its components. J Chromatogr 1972;72:71–82.

    PubMed  CAS  Google Scholar 

  149. Tu AT, Tu T. Sea snakes from southeast Asia and the Far East and their venoms. In: Halstead, B.W., Editor, Poisonous and Venomous Marine Animals of the World Vol. 3, U.S. Government Printing Office, Washington, DC, 1970 pp. 885–903..

    Google Scholar 

  150. Barme M. Venomous sea snakes of Viet Nam and their venoms. In Venomous and Poisonous Animals and Noxious Plants of the Pacific Region, ed. by H. L. Keegan and W. V. McFarlane. The Macmillan Co., New York, 1963 pp. 373–378.

    Google Scholar 

  151. Karlsson E. Chemistry of protein toxins in snake venoms. In: Lee, C.Y., Editor, Snake Venoms, Handbook of Experimental Pharmacology vol. 52, Springer, Berlin, 1979 pp. 159–212.

    Google Scholar 

  152. Chang CC, Su MJ. Mutual potentiation a nerve terminals, between toxins from snake venoms that contain phospholipase A activity: β–bungarotoxin, crotoxin, taipoxin. Toxicon 1980;18:641–648.

    PubMed  CAS  Google Scholar 

  153. Rowlands JB, Mastaglia FL, Kakulas BA, Hainsworth D. Clinical and pathological aspects of a fatal case of mulga (Pseudechis australis) snakebite. Med J Aust 1969;1:226–230.

    PubMed  CAS  Google Scholar 

  154. Kellaway CH. The peripheral action of the Australian snake venoms. 2. The curari-like action in mammals. Aust J Exp Biol Med Sci 1932;10:181–194.

    CAS  Google Scholar 

  155. Bouquier JJ, Guibert J, Dupont C, Umdenstock R. Les piqures de vipere chez l'enfant. Archives Francaises de Pediatrie 1974;31:285–296.

    PubMed  CAS  Google Scholar 

  156. Mitrakul C, Dhamkrong-At A, Futrakul P, Thisyakorn C, Vongsrisart K, Varavithya C, Phancharoen S. Clinical features of neurotoxic snake bite and response to antivenom in 47 children. Am J Trop Med Hyg 1984;33:1258–1266.

    PubMed  CAS  Google Scholar 

  157. Reid HA. Cobra-bites. Br Med J 1964;2:540–545.

    PubMed  CAS  Google Scholar 

  158. Warrell DA, Barnes HJ, Piburn MF. Neurotoxic effects of bites by the Egyptian cobra (Naja haje) in Nigeria. Trans R Soc Trop Med Hyg 1976;70:78–79.

    PubMed  CAS  Google Scholar 

  159. Kerrigan KR. Venomous snake bites in Eastern Ecuador. Am J Trop Med Hyg 1991;44:93–99.

    PubMed  CAS  Google Scholar 

  160. Ouyang C, Teng C-M, Huang T-F. Characterization of snake venom components acting on blood coagulation and platelet function. Toxicon 1992;30:945–966.

    PubMed  CAS  Google Scholar 

  161. Reid HA. Antivenom in sea-snake bite poisoning. Lancet 1975;i:622–623.

    Google Scholar 

  162. Theakston RDG, Phillips RE, Warrell DA, Galagedera Y, Abeysekera DTDJ, Dissanayaka P, De Silva A, Aloysius DJ. Envenoming by the common krait (Bungarus caeruleus) and Sri Lankan cobra (Naja naja naja): efficacy and complications with Haffkine antivenom. Trans R Soc Trop Med Hyg 1990;84:301–308.

    PubMed  CAS  Google Scholar 

  163. Kumar S, Usgaonkar RS. Myasthema gravis like picture resulting from snake bite. J Indian Med Assoc 1968;50:428–429.

    PubMed  CAS  Google Scholar 

  164. Pettigrew LC, Glass JP. Neurologic complications of coral snake bite. Neurology 1985;35:589–592.

    PubMed  CAS  Google Scholar 

  165. Southcott RV. The neurologic effects of noxious marine creatures. Contemp Neurol Ser 1975;165–258.

    Google Scholar 

  166. Steidinger KA, Steinfield HJ. Toxic marine dinoflagellates. In: Spector DL, ed. Dinoflagellates. New York, Academic. 1984;201–206.

    Google Scholar 

  167. Olivera BM, Gray WR, Zeikus R, McIntosh JM, Varga J, Rivier J, de Santos V, Cruz LJ. Peptide neruotoxins from fish-hunting cone snails. Science 1985;230:1338–1343.

    PubMed  CAS  Google Scholar 

  168. Kohn AJ. Venomous marine snails of the genus Conus. In Venomous and Poisonous Animals and Noxious Plants of the Pacific Region, ed. by H. L. Keegan and W. V. McFarlane. Permagon Press, The Macmillan Co., New York, 1963 pp. 83.

    Google Scholar 

  169. Kohn AJ. Recent cases of human injury due to venomous marine snails of the genus Conus. Hawaii Med J Inter-Island Nurses' Bulletin 1958;17:528–532.

    CAS  Google Scholar 

  170. Cruz LJ, White J. Clinical toxicology of Conus snail stings. In: Clinical Toxicology of Animal Venoms, ed. J. Meier, and J. White, Boca Raton FL: CRC Press, 1995 pp. 117–127.

    Google Scholar 

  171. Gray WR, Luque A, Olivera BM, Barrett J, Cruz LJ. Peptide toxins from Conus geographus venom. J Biol Chem 1981;256:4734–4740.

    PubMed  CAS  Google Scholar 

  172. Hopkins C, Grilley M, Miller C, Shon KJ, Cruz LJ, Gray WR, Dykert J, Rivier J, Yoshikami D, Olivera BM. A new family of Conus peptides targeted tothe nicotinic acetylcholine receptor. J Biol Chem 1995;270:22361–22367.

    PubMed  CAS  Google Scholar 

  173. McIntosh M, Cruz LJ, Hunkapiller MW, Gray WR, Olivera BM. Isolation and structure of a peptide toxin from the marine snail Conus magnus. Arch Biochem Biophys 1982;218:329–334.

    PubMed  CAS  Google Scholar 

  174. McCleskey EW, Fox AP, Feldman D, Cruz LJ, Olivera BM, Tsien RW, Yoshikami D. Calcium channel blockade by a peptide from Conus: specificity and mechanism. Proc Natl Acad Sci U S A 1987;84:4327–4331.

    PubMed  CAS  Google Scholar 

  175. Adams DJ, Alewood PF, Craik DJ, Drinkwater RD, Lewis RJ. Conotoxins and their potential pharmaceutical applications. Drug Dev Res 1999;46:219–234.

    CAS  Google Scholar 

  176. De Aizpurua HJ, Lambert EH, Griesmann GE, Olivera M, Lennon VA. Antagonism of voltage-gated calcium channels in small cell carcinomas of patients with and without Lambert-Eaton myasthenic syndrome by autoantibodies omega-conotoxin and adenosine. Cancer Res 1988;48:4719–4724.

    PubMed  Google Scholar 

  177. Yoshiba S. [An estimation of the most dangerous species of cone shell, Conus (Gastridium) geographus Linne, 1758, venom's lethal dose in humans]. Japanese J Hyg 1984;39:565–572.

    CAS  Google Scholar 

  178. Halstead BW. Poisonous and venomous marine animals (U.S.Govt.Print.Office, Wash.DC, vol 2, 1967, vol 3 1970.

    Google Scholar 

  179. Gwee MC, Gopalakrishnakone P, Yuen R, Khoo HE, Low KS. A review of stonefish venoms and toxins. Pharmacol Ther 1994;64:509–528.

    PubMed  CAS  Google Scholar 

  180. Kreger AS, Molgo J, Comella JX, Hansson B, Thesleff S. Effects of stonefish (Synanceia trachynis) venom on murine and frog neruomuscular junctions. Toxicon 1993;31:307–317.

    PubMed  CAS  Google Scholar 

  181. Hardin JW, Arena JM. Human Poisoning from Native and Cultivated Plants. 2nd edition, Duke University Press, Durham, NC. 1974.

    Google Scholar 

  182. Davies ML, Davies TA. Hemlock: murder before the lord. Med Sci Law 1994;34:331–333.

    PubMed  CAS  Google Scholar 

  183. Panter K E, Keeler RF. Piperidine alkaloids of poison hemlock (Conium maculatum). In Cheeke, PR., ed. Toxicants of plant origin. Vol. I. Alkaloids. CRC Press, Inc., Boca Raton, 1989. pp. 109–132.

    Google Scholar 

  184. Silinsky EM. On the role of barium in supporting the asynchronous release of acetylcholine quanta by moter nerve impulses. J Physiol (Lond) 1978;274:157–171.

    CAS  Google Scholar 

  185. Silinsky EM. Can barium support the release of acetylcholine by nerve impulses? Br J Pharmacol 1977;59:215–217.

    PubMed  CAS  Google Scholar 

  186. Metral S, Bonneton C, Hort-Legrand C, Reynes J. Dual action of erbium on transmitter release at the from neuromuscular synapse. Nature 1978;271:773–775.

    PubMed  CAS  Google Scholar 

  187. Cooper GP, Manalis RS. Cadmium: effects on transmitter release a the frog neuromuscular junction. Eur J Pharmacol 1984;99:251–256.

    PubMed  CAS  Google Scholar 

  188. Forshaw PJ. The inhibitory effect of cadmium on neuromuscular transmission in the rat. Eur J Pharmacol 1977;42:371–377.

    PubMed  CAS  Google Scholar 

  189. Weakly JN. the action of cobalt ions on neruomusculal transmission in the frog. J Physiol (Lond) 1973;234:597–612.

    CAS  Google Scholar 

  190. Molgo J, del Pozo E, Banos JE, Angaut-Petit D. Changes in quantal transmitter release caused by gadolinium ions at the frog neuromuscular junction. Br J Pharmacol 1991;104:133–138.

    PubMed  CAS  Google Scholar 

  191. Kajimoto N, Kirpekar SM. Effects of manganese and lanthanum on spontaneous release of acetylcholine at frog motor nerve terminals. Nature 1972;235:29–30.

    CAS  Google Scholar 

  192. Balnave RJ, Gage PW. The inhibitory effect of manganese on transmitter release at the neuromuscular junction of the toad. Br J Pharmacol 1973;47:339–352.

    PubMed  CAS  Google Scholar 

  193. Kita H, Van der Kloot W. Action of Co and Ni at the frog neuromuscular junction. Nature 1973;245:52–53.

    CAS  Google Scholar 

  194. Alnaes E, Rahaminoff R. Dual action of praseodymium (Pr3+) on transmitter release at the frog neuromuscular synapse. Nature 1975;247:479

    Google Scholar 

  195. Allen JE, Gage PW, Leaver DD, Leow ACT. Triethyltin decreases evoked transmitter release at the mouse neuromuscular junction. Chem Biol Interact 1980;31:227–231.

    PubMed  CAS  Google Scholar 

  196. Benoit PR, Mambrini J. Modification of transmitter release by ions which prolong the presynaptic action potential. J Physiol (Lond) 1970;210:681–695.

    CAS  Google Scholar 

  197. Cooper GP, Manalis RS. Influence of heavy metals on synaptic transmission. Neurotoxicology 2001;4:69–84.

    Google Scholar 

  198. Rustam H, Hamdi T. Methylmercury poisoning n Iraq; a neurological study. Brain 1974;97:499–510.

    Google Scholar 

  199. Bakir F, Damluji SF, Amin-Saki L, Murthada M, Khalida A, Al-Rawi NY, Tikriti S, Dhahir HJ, Clarkson T, Smith JC, Doherty RA. Methylmercury poisoning in Iraq. Science 1973;181:230–241.

    PubMed  CAS  Google Scholar 

  200. Igata A. Neurological aspects of methylmercury poisoning in Minamata. In: Tsubaki T, Takahashi H (eds) Recent advances in Minamata disease studies. Kodansha, Tokyo, 1986 pp 41–57.

    Google Scholar 

  201. LeQuense P, Damluji SF, Berlin M. Electrophysiological studies of peripheral nerves in patients with organic mrcury poisoning. J Neurol Neurosurg Psychiatry 1974;37:333–339.

    Google Scholar 

  202. Rustam H, von Burg R, Amin-Saki L, Elhassani S. Evidence of a neuromuscular disorder in methymercury poisoning. Arch Environ Health 1975;30:190–195.

    PubMed  CAS  Google Scholar 

  203. Atchinson WD, Narahashi T. Methylmercury induced depression of neuromuscular transmission in the rat. Neurotoxicology 1982;3:37–50.

    Google Scholar 

  204. Taylor P. Anticholinesterase agents. In: Gilman, AG, Goodman, LS, Rall, T.W. and Murad, F., Editors, The Pharmacological Basis of Therapeutics, Macmillan, New York, 1985 pp. 110–129.

    Google Scholar 

  205. Edmundson RS. Dictionary of organphosphorous compounds [electronic resource]. 1988

    Google Scholar 

  206. Gunderson CH, Lehmann CR, Sidell FR, Jabari B. Nerve effects: a review. Neurology 1992;42:946–950.

    PubMed  CAS  Google Scholar 

  207. Fernando, R. Pesticides in Sri Lanka, Documentation of selected literature and legal aspects. Friedrich-Ebert Press-Colombo. 1989 pp. 27–34.

    Google Scholar 

  208. Besser R, Gutmann L, Dilimann U, Weilemann LS, Hopf HC. End plate dysfunction in acute organophosphate intoxication. Neurology 1989;39:561–567.

    PubMed  CAS  Google Scholar 

  209. Gutmann L, Besser R. Organophosphate intoxication: pharmacologic, neurophysiologic, clinical, and therapeutic considerations. Semin Neurol 1990;10:46–51.

    PubMed  CAS  Google Scholar 

  210. Jeyaratnam J. Acute pesticide poisoning: a major health problem. World Health Stat Q 1990;43:139–145.

    PubMed  CAS  Google Scholar 

  211. Aldridge WN, Reiner E. Enzyme Inhibitors as Substrates. Interactions of Esterases with Esters of Organophosphorus and Carbamic Acids, North Holland, Amsterdam 1972 pp. 1–328.

    Google Scholar 

  212. Marrs TC. Organophosphate poisoning. Pharmacol Ther 1993;58:51–66.

    PubMed  CAS  Google Scholar 

  213. Namba T, Nolte CT, Jackrel J, Grob D. Poisoning due to organophosphorous insecticides. Am J Med 2001;50:475–492.

    Google Scholar 

  214. Karalliedde L, Senanayake N. Organophosphorous insecticide poisoning. Br J Anaesth 1989;63:736–750.

    PubMed  CAS  Google Scholar 

  215. De Wilde V, Vogblaers D, Colarddyn F, Vanderstraeten G, Van Den Neucker K, De Bleecker J, De Reuck J, Van den Neede M. Postsynaptic neuromuscular dysfunction in orgaophosphate induced intermediate syndrome. Klinische Wochenschrift 1991;69:177–183.

    PubMed  Google Scholar 

  216. Good JL, Khurana RK, Mayer RF, Cintra WM, Albuquerque EX. Pathophysiological studies of neuromuscular function in subacute organophosphate poisoning induced by phosmet. J Neurol, Neurosurg Psychiatry 1993;56:290–294.

    CAS  Google Scholar 

  217. Maselli RA, Soliven BC. Analysis of the organophosphate-induced electromyographic response to repetitive nerve stimulation: paradoxical response to edrophonium and D-tubocurarine. Muscle Nerve 1991;14:1182–1188.

    PubMed  CAS  Google Scholar 

  218. Tsao TC, Juang Y, Lan R, Shieh W, Lee C. Respiratory failure of acute organophosphate and carbamate poisoning. Chest 1990;98:631–636.

    PubMed  CAS  Google Scholar 

  219. Anonymous. Public Health Impact of Pesticides Used in Agriculture, World Health Organization/UNEP, 1990 pp. 1–128.

    Google Scholar 

  220. Haddad LM. Organophosphate poisoning – Intermediate syndrome. J Toxicol:Clin Toxicol 1992;30:331–332.

    Google Scholar 

  221. De Bleecker J, Willems J, Van Den Neucker K, De Reuck J, Vogelaers D. Prolonged toxicity with intermediate syndrome after combined parathion and methyl parathion poisoning. Clin Toxicol 1992;30:333–345.

    Google Scholar 

  222. Güler K, Tasçioglu C, Özbey N. Organophosphate poisoning. Isr J Med Sci 1996;32:791–792.

    PubMed  Google Scholar 

  223. Chaudhry R, Lall SB, Mishra B, Dhawan B. Lesson of the week – a foodborne outbreak of organophosphate poisoning. Br Med J 1998;317:268–269.

    CAS  Google Scholar 

  224. Cranmer MF. Carbaryl. A toxicological review and risk analysis. Neurotoxicology 1986;7:247–328.

    PubMed  CAS  Google Scholar 

  225. Goldman LR, Smith DF, Neutra RR, Saunders LD, Pond EM, Stratton J, Waller K, Jackson J, Kizer KW. Pesticide food poisoning from contaminated watermelons in California. Arch Environ Health 1990;45:229–236.

    PubMed  CAS  Google Scholar 

  226. Freslew KE, Hagardorn AN, McCormick WF. Poisoning from oral ingestion of carbofuran (Furandan 4F), a cholinesterase-inhibiting carbamate insecticide, and its effects on cholinesterase activity in various biological fluids. J Forensic Sci 1992;37:337–344.

    Google Scholar 

  227. Jenis EH, Payne RJ, Goldbaum LR. Acute meprobamate poisoning: a fatal case following a lucid interval. J Am Med Assoc 1969;207:361–362.

    CAS  Google Scholar 

  228. Klys M, Kosún J, Pach J, Kamenczak A. Carbofuran poisoning of pregnant women and fetus per injestion. J Forensic Sci 1989;34:1413–1416.

    PubMed  CAS  Google Scholar 

  229. Maddock RK, Bloomer HA. Meprobamate overdosage. Evaluation of its severity and methods of treatment. J Am Med Assoc 1967;201:123–127.

    Google Scholar 

  230. Ecobichon DJ. Carbamate Insecticides. Ch. 52. In Handbook of Pesticide Toxicology, R. Krieger (Ed.), Academic Press, 2001 pp. 1087–1106.

    Google Scholar 

  231. Maynard RL, Ballantyne B, Marrs T, Turner P. Toxicology of chemical warfare agents Stockton Press, New York, NY (USA). 1993.

    Google Scholar 

  232. Spencer PS, Wilson BW, Albuquerque EX. Sarin other nerve agents, and their antidotes. In Experimental and Clinical Neurotoxicology, 2nd Ed., P.S. Spencer, and H.H. Schaumburg, eds. New York: Oxford University Press. 2000 pp. 1073–1093.

    Google Scholar 

  233. Meselson M, Perry Robinson J. Chemical warfare and disarmament. Sci Am 1980;242:34–47.

    Google Scholar 

  234. Nozaki H, Aikawa N, Fujishima S, Suzuki M, Shinozawa Y, Hori S, Nogawa S. A case of VX poisoning and the difference from sarin. Lancet 1995;346:698–699.

    PubMed  CAS  Google Scholar 

  235. Nozaki H, Aikawa N, Shinozawa Y, Hori S, Fujishima S, Takuma K, Sagoh M. Sarin poisoning in Tokyo subway. Lancet 1995;345:980–981.

    PubMed  CAS  Google Scholar 

  236. Morita H, Yanagisawa N, Nakajima T, Shimizu M, Hirabayashi H, Okudera H, Nohara M, Midorikawa Y, Mimura S. Sarin poisoning in Matsumoto, Japan. Lancet 1995;346:290–293.

    PubMed  CAS  Google Scholar 

  237. Nakajima T, Saro S, Morita H, Yanagisawa N. Sarin poisoning of a rescue team in the Matsumoto sarin incident in Japan. Occup Environ Med 1997;54:697–701.

    PubMed  CAS  Google Scholar 

  238. Woodall J. Tokyo subway gas attack. Lancet 1997;350:296.

    PubMed  CAS  Google Scholar 

  239. Dunn MA, Hackley BE, Sidell FR. Pretreatment for nerve agent exposure. In Sidell FR, Takafuji ET, Franz DR, eds. Textbook of Military Medicine: Medical Aspects of Chemical and Biological Warfare. Washington, DC: Borden Institute, Walter Reed Army Medical Center; 1997:pp. 181–196.

    Google Scholar 

  240. Dawson RM. Review of oximes available for treatment of nerve agent poisoning. J Appl Toxicol 1994;14:317–331.

    PubMed  CAS  Google Scholar 

  241. Worek F, Szinicz L, Eyer P, Thiermann H. Evaluation of oxime efficacy in nerve agent poisoning: development of a kinetic-based dynamic model. Toxicol Appl Pharmacol 2005;209:193–202.

    PubMed  CAS  Google Scholar 

  242. Holstege CP, Kirk M, Sidell FR. Chemical warfare. Nerve agent poisoning. Criti Care Med 1997;13:923–942.

    CAS  Google Scholar 

  243. Dawson RM. Review of oximes available for treatment of nerve agent poisoning. J Appl Toxicol 1994;14:317–331.

    PubMed  CAS  Google Scholar 

  244. Becker G, Kawan A, Szinicz L. Direct reaction of oximes with sarin, soman or tabun in vitro. Arch Toxicol 1997;71:714–718.

    PubMed  CAS  Google Scholar 

  245. Ecobichon DJ. Carbamic acid ester insecticides. In: D.J. Ecobichon and R.M. Joy, Editors, Pesticides and Neurobiological Diseases (2nd Edition ed.),, CRC, Boca Raton, FL 1994 pp. 313–351.

    Google Scholar 

  246. Rotenberg M, Shefi M, Dany S, Dore I, Tirosh M, Almog S. Differentiation between organophosphate and carbamate poisoning. Clinica Chimica Acta 1995;234:11–21.

    CAS  Google Scholar 

  247. Besser R, Vogt T, Gutmann L. High pancuronium sensitivity of axonal nicotinic-acetylcholine receptors in humans during organophosphate intoxication. Muscle Nerve 1991;14:1197–1201.

    PubMed  CAS  Google Scholar 

  248. Miller SA, Blick DW, Kerenyi SZ, Murphy MR. Efficacy of physostigmine as a pretreatment for organophosphate poisoning. Pharmacol Biochem Behav 1993;44:343–347.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, The University of North Carolina, Chapel Hill, NC

    James F. Howard (Jr)

Authors
  1. James F. Howard
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Humana Press, a part of Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Howard, J.F. (2009). Toxic Neuromuscular Transmission Disorders. In: Myasthenia Gravis and Related Disorders. Current Clinical Neurology. Humana Press. https://doi.org/10.1007/978-1-59745-156-7_16

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-156-7_16

  • Published:

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-852-2

  • Online ISBN: 978-1-59745-156-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation